Financial Performance - The company incurred a net loss of $642,266 for the three months ended September 30, 2025, and a total net loss of $42.1 million since its incorporation on November 14, 2017 [77][80]. - Revenue for the three months ended September 30, 2025, was $94,296, a significant increase from $11,250 for the same period in 2024, reflecting a strategic pivot to grow the customer base [97]. Cash and Funding - Cash, cash equivalents, and restricted cash totaled $1,930,053 as of September 30, 2025, down from $2,433,418 as of June 30, 2025 [84][90]. - The company has raised approximately $11.76 million from private placements and $12.8 million from a public offering of common stock in September 2020 [81]. Deferred Revenue and Liabilities - Deferred revenue liabilities totaled $24,655 as of September 30, 2025, down from $36,745 as of June 30, 2025, indicating a reduction in future performance obligations [96]. Expenses - General and administrative expenses decreased to $547,060 for the three months ended September 30, 2025, from $633,122 in the same period in 2024, due to lower payroll costs [101]. - Technology and content development expenses were $102,888 for the three months ended September 30, 2025, compared to $139,658 for the same period in 2024, reflecting reduced headcount [103]. - Sales and marketing expenses decreased to $106,472 for the three months ended September 30, 2025, from $165,814 in the same period in 2024, as marketing functions were moved in-house [105]. Capitalization and Amortization - The company capitalized software costs of $87,600 for the three months ended September 30, 2025, and recognized amortization expense of $54,103 during the same period [92]. Interest Income - Interest income for the three months ended September 30, 2025, was $19,858, slightly up from $19,299 for the same period in 2024 [106].

PART I [ITEM 1. BUSINESS](index=7&type=section&id=Item%201.%20Business) Amesite Inc. pivoted in fiscal 2025 to focus on AI-powered solutions for the healthcare sector, specifically post-acute care, under its NurseMagic™ brand, while maintaining Amesite Engage for existing users - Amesite Inc. completed a **strategic pivot in fiscal 2025** from an education-centric model to focus on **AI-powered solutions for the healthcare sector**, particularly the post-acute care market[20](index=20&type=chunk) - The company operates **two product lines under the NurseMagic™ brand**: a B2C app for direct-to-practitioner use and a B2B enterprise platform for healthcare businesses (home health, skilled nursing, hospice, non-clinical segments)[21](index=21&type=chunk)[22](index=22&type=chunk)[23](index=23&type=chunk) - **Amesite Engage platform** remains a performant solution for its user base, but resources are **not dedicated to its growth**[25](index=25&type=chunk) [Overview](index=7&type=section&id=Overview) [Our Sales and Marketing Motions](index=8&type=section&id=Our%20Sales%20and%20Marketing%20Motions) [Our Technology and Pipeline](index=8&type=section&id=Our%20Technology%20and%20Pipeline) [Our Intellectual Property](index=9&type=section&id=Our%20Intellectual%20Property) [Competition](index=9&type=section&id=Competition) [Government Regulation and Product Approval](index=9&type=section&id=Government%20Regulation%20and%20Product%20Approval) [Sales and Marketing](index=10&type=section&id=Sales%20and%20Marketing) [Board of Advisors](index=10&type=section&id=Board%20of%20Advisors) [Human Capital Management](index=12&type=section&id=Human%20Capital%20Management) [Corporate Information](index=12&type=section&id=Corporate%20Information) [ITEM 1A. RISK FACTORS](index=14&type=section&id=Item%201A.%20Risk%20Factors) Amesite faces significant risks including stringent regulatory compliance, intense competition, challenges in market adoption, technology risks, and financial concerns about its ability to continue as a going concern - The healthcare sector is **highly regulated**, and non-compliance with laws like HIPAA, HITECH, CMS, and emerging AI regulations could lead to **significant penalties, legal action, or business restrictions**[64](index=64&type=chunk)[65](index=65&type=chunk) - The healthcare software industry is **intensely competitive**, with established platforms and numerous AI-first entrants, many with greater resources[66](index=66&type=chunk) - Amesite has incurred **net losses** in recent fiscal years and has not yet established a stable, recurring revenue base sufficient to cover ongoing expenses, leading to **substantial doubt about its ability to continue as a going concern**[70](index=70&type=chunk)[77](index=77&type=chunk) - The company is **dependent on key management personnel**, employees, advisors, and consultants, and the loss of such individuals or failure to attract new talent could hinder growth[80](index=80&type=chunk) - **Cybersecurity and data protection risks** are inherent in managing health-related and personal information, with potential for **severe financial, reputational, and legal consequences** from breaches[69](index=69&type=chunk)[92](index=92&type=chunk)[95](index=95&type=chunk) [ITEM 1B. UNRESOLVED STAFF COMMENTS](index=24&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) There are no unresolved staff comments from the SEC - The company has **no unresolved staff comments**[121](index=121&type=chunk) [ITEM 1C. CYBERSECURITY](index=24&type=section&id=Item%201C.%20Cybersecurity) Amesite Inc. has a formal, documented process for cybersecurity risk management, with board oversight, and has not experienced material incidents recently, though future threats are acknowledged - Amesite Inc. follows a **formal, documented process for cybersecurity risk management**, including assessing third-party vendors handling sensitive information[122](index=122&type=chunk) - The **board of directors has oversight** over cybersecurity risks, with management providing periodic updates on the cybersecurity program and strategy[124](index=124&type=chunk) - While **no material cybersecurity threats or incidents** have been experienced in recent years, the company acknowledges the possibility of future threats[123](index=123&type=chunk)[125](index=125&type=chunk) [ITEM 2. PROPERTIES](index=24&type=section&id=Item%202.%20Properties) Amesite Inc. operates remotely with its corporate headquarters in Detroit, Michigan, and believes its current setup is adequate, with suitable alternative space available if needed - Amesite Inc. **operates remotely with no lease obligations**, with its corporate headquarters listed in Detroit, Michigan[126](index=126&type=chunk) - The company believes its **current remote setup is sufficient** and that alternative space can be secured on reasonable terms if needed[126](index=126&type=chunk) [ITEM 3. LEGAL PROCEEDINGS](index=24&type=section&id=Item%203.%20Legal%20Proceedings) Amesite Inc. is not currently involved in any legal proceedings expected to materially adversely affect its business, financial condition, or results of operations - Amesite Inc. is **not currently involved in any legal proceedings** expected to have a material adverse effect on its business or financial results[127](index=127&type=chunk) [ITEM 4. MINE SAFETY DISCLOSURES](index=24&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to Amesite Inc - Mine Safety Disclosures are **not applicable** to the company[128](index=128&type=chunk) PART II [ITEM 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=25&type=section&id=Item%205.%20Market%20For%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Amesite Inc.'s common stock trades on Nasdaq under "AMST", with approximately 41 stockholders, and the company has never paid cash dividends, intending to retain earnings for business development - Amesite Inc.'s common stock is traded on the **Nasdaq Capital Market** under the symbol "**AMST**"[130](index=130&type=chunk) - As of September 29, 2025, there were approximately **41 stockholders of record**[130](index=130&type=chunk) - The company has **never paid cash dividends** and does not anticipate paying any in the foreseeable future, planning to retain all available funds for business development and expansion[131](index=131&type=chunk) - During the year ended June 30, 2025, **121,250 options** to purchase common stock were issued to employees under the 2018 Equity Incentive Plan[132](index=132&type=chunk) [ITEM 6. [RESERVED].](index=25&type=section&id=Item%206.%20%5BRESERVED%5D.) This item is reserved and contains no information [ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Amesite Inc. reported a net loss of $3.6 million in FY2025, raising going concern doubts, with revenue decreasing due to a strategic pivot to NurseMagic™ in healthcare, while operating expenses decreased due to cost savings - Amesite Inc. incurred a **net loss of $3,617,086** for the twelve months ended June 30, 2025, and a **cumulative net loss of $41,450,587** from inception to June 30, 2025[137](index=137&type=chunk) - Management believes there is **substantial doubt about the company's ability to continue as a going concern** due to recurring losses and negative cash flows, with plans to generate cash through financing transactions[138](index=138&type=chunk)[139](index=139&type=chunk) - The company **strategically pivoted from education-focused offerings to the NurseMagic™ app for healthcare** in late fiscal year 2024, with initial sales in Q2 FY2025 and HIPAA compliance achieved in April 2025[169](index=169&type=chunk) Revenue Performance (FY2024 vs. FY2025) | Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 | Change (YoY) | | :----------------------- | :----------------------- | :----------------------- | :------------- | | Net Revenue | $110,459 | $166,881 | -$56,422 (-33.8%) | Operating Expenses (FY2024 vs. FY2025) | Expense Category | Year Ended June 30, 2025 | Year Ended June 30, 2024 | Change (YoY) | | :------------------------------- | :----------------------- | :----------------------- | :------------- | | General and administrative | $2,477,888 | $2,908,289 | -$430,401 (-14.8%) | | Technology and content development | $691,154 | $1,074,328 | -$383,174 (-35.7%) | | Sales and marketing | $545,030 | $763,915 | -$218,885 (-28.6%) | | Total Operating Expenses | $3,714,072 | $4,746,532 | -$1,032,460 (-21.7%) | Net Loss (FY2024 vs. FY2025) | Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 | Change (YoY) | | :------- | :----------------------- | :----------------------- | :------------- | | Net Loss | $(3,617,000) | $(4,403,000) | $786,000 (17.8%) decrease in loss | [Overview](index=26&type=section&id=Overview_MD%26A) [Basis of Presentation](index=26&type=section&id=Basis%20of%20Presentation) [Critical Accounting Policies and Significant Judgments and Estimates](index=26&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) [Financial Position, Liquidity, and Capital Resources](index=30&type=section&id=Financial%20Position%2C%20Liquidity%2C%20and%20Capital%20Resources) [ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk](index=31&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) Amesite Inc. is exempt from providing quantitative and qualitative disclosures about market risk due to its status as a "smaller reporting company" - Amesite Inc. is **not required to provide quantitative and qualitative disclosures about market risk** due to its status as a "**smaller reporting company**"[175](index=175&type=chunk) [ITEM 8. Financial Statements and Supplementary Data](index=33&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents Amesite Inc.'s audited financial statements for FY2025 and FY2024, including balance sheets, statements of operations, stockholders' equity, and cash flows, with auditors expressing substantial doubt about going concern - Independent auditors' reports for both 2025 and 2024 express **substantial doubt about the Company's ability to continue as a going concern** due to recurring losses and negative cash flows from operations[181](index=181&type=chunk)[188](index=188&type=chunk) Balance Sheet Highlights (June 30, 2025 vs. 2024) | Metric | June 30, 2025 | June 30, 2024 | | :------------------------- | :------------ | :------------ | | Cash and cash equivalents | $2,333,418 | $2,071,016 | | Total current assets | $2,433,859 | $2,504,565 | | Total assets | $3,097,099 | $3,314,177 | | Total current liabilities | $358,596 | $798,465 | | Total stockholders' equity | $2,738,503 | $2,515,712 | Statements of Operations Highlights (FY2025 vs. FY2024) | Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 | | :------------------------- | :----------------------- | :----------------------- | | Net Revenue | $110,459 | $166,881 | | Total operating expenses | $3,714,072 | $4,746,532 | | Loss from Operations | $(3,603,613) | $(4,579,651) | | Net Loss | $(3,617,086) | $(4,403,182) | | Basic and diluted loss per share | $(1.03) | $(1.73) | Cash Flows from Operating Activities (FY2025 vs. FY2024) | Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 | | :-------------------------------------- | :----------------------- | :----------------------- | | Net cash used in operating activities | $(2,455,248) | $(2,813,779) | | Net cash used in investing activities | $(378,300) | $(375,866) | | Net cash provided by financing activity | $3,095,950 | $0 | | Net increase (decrease) in cash | $262,402 | $(3,189,645) | [Report of Independent Registered Public Accounting Firm (Novogradac & Company LLP)](index=34&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm%20%28Novogradac%20%26%20Company%20LLP%29) [Report of Independent Registered Public Accounting Firm (Turner, Stone & Company, L.L.P.)](index=35&type=section&id=REPORT%20OF%20INDEPENDENT%20REGISTERED%20PUBLIC%20ACCOUNTING%20FIRM_Turner) [Balance Sheets](index=36&type=section&id=Balance%20Sheets) [Statements of Operations](index=37&type=section&id=Statements%20of%20Operations) [Statements of Changes in Stockholders' Equity](index=38&type=section&id=Statements%20of%20Changes%20in%20Stockholders%27%20Equity) [Statements of Cash Flows](index=39&type=section&id=Statements%20of%20Cash%20Flows) [Notes to Financial Statements](index=40&type=section&id=Notes%20to%20Financial%20Statements) [Note 1 - Nature of Business and Liquidity](index=40&type=section&id=Note%201%20-%20Nature%20of%20Business%20and%20Liquidity) [Note 2 - Significant Accounting Policies](index=40&type=section&id=Note%202%20-%20Significant%20Accounting%20Policies) [Note 3 - Property and Equipment and Capitalized Software](index=46&type=section&id=Note%203%20-%20Property%20and%20Equipment%20and%20Capitalized%20Software) [Note 4 - Common Stock](index=47&type=section&id=Note%204%20-%20Common%20Stock) [Note 5 - Warrants](index=48&type=section&id=Note%205%20-%20Warrants) [Note 6 - Stock-Based Compensation](index=49&type=section&id=Note%206%20-%20Stock-Based%20Compensation) [Note 7 - Income Taxes](index=51&type=section&id=Note%207%20-%20Income%20Taxes) [Note 8 – Segment Information](index=53&type=section&id=Note%208%20%E2%80%93%20Segment%20Information) [Note 9 – Related Party Transactions](index=53&type=section&id=Note%209%20%E2%80%93%20Related%20Party%20Transactions) [Note 10 - Subsequent Events](index=53&type=section&id=Note%2010%20-%20Subsequent%20Events) [ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](index=54&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20With%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) Amesite Inc. reports no changes in or disagreements with its accountants on accounting and financial disclosure matters - There were **no changes in or disagreements** with accountants on accounting and financial disclosure[290](index=290&type=chunk) [ITEM 9A. Controls and Procedures](index=54&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective, and the company is exempt from auditor attestation due to its "emerging growth company" status - Disclosure controls and procedures were evaluated as **effective as of June 30, 2025**[291](index=291&type=chunk) - Management concluded that internal control over financial reporting was **effective as of June 30, 2024**[294](index=294&type=chunk) - The company is **exempt from auditor attestation** on internal control over financial reporting due to its "**emerging growth company**" status[295](index=295&type=chunk) [ITEM 9B. Other Information](index=54&type=section&id=Item%209B.%20Other%20Information) No directors or executive officers adopted, modified, or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - **No directors or executive officers adopted, modified, or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements** during the quarter ended June 30, 2025[297](index=297&type=chunk) [ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](index=54&type=section&id=Item%209C.%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections) This item is not applicable to Amesite Inc - Disclosure regarding foreign jurisdictions that prevent inspections is **not applicable** to the company[298](index=298&type=chunk) PART III [ITEM 10. Directors, Executive Officers and Corporate Governance](index=55&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information for this item is incorporated by reference from the registrant's definitive proxy statement for its next Annual Meeting of Stockholders - Information regarding Directors, Executive Officers, and Corporate Governance is **incorporated by reference** from the definitive proxy statement[300](index=300&type=chunk) [ITEM 11. Executive Compensation](index=55&type=section&id=Item%2011.%20Executive%20Compensation) Information for this item is incorporated by reference from the registrant's definitive proxy statement for its next Annual Meeting of Stockholders - Information regarding Executive Compensation is **incorporated by reference** from the definitive proxy statement[301](index=301&type=chunk) [ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=55&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information for this item is incorporated by reference from the registrant's definitive proxy statement for its next Annual Meeting of Stockholders - Information regarding Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters is **incorporated by reference** from the definitive proxy statement[302](index=302&type=chunk) [ITEM 13. Certain Relationships and Related Transactions, and Director Independence](index=55&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information for this item is incorporated by reference from the registrant's definitive proxy statement for its next Annual Meeting of Stockholders - Information regarding Certain Relationships and Related Transactions, and Director Independence is **incorporated by reference** from the definitive proxy statement[303](index=303&type=chunk) [ITEM 14. Principal Accountant Fees and Services](index=55&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information for this item is incorporated by reference from the registrant's definitive proxy statement for its next Annual Meeting of Stockholders - Information regarding Principal Accountant Fees and Services is **incorporated by reference** from the definitive proxy statement[304](index=304&type=chunk) PART IV [ITEM 15. Exhibits and Financial Statement Schedules](index=56&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section details the financial statements and a comprehensive list of exhibits, including corporate governance documents and agreements, filed with or incorporated by reference into the Form 10-K - The report includes **audited financial statements**: Report of Independent Registered Public Accounting Firm, Balance Sheets, Statements of Operations, Statements of Changes in Stockholders' Equity, Statements of Cash Flows, and Notes to Financial Statements[306](index=306&type=chunk) - All financial statement schedules have been **omitted** as they are not applicable, not required, or the information is presented within the financial statements or notes[306](index=306&type=chunk) - A **detailed list of exhibits**, including corporate documents, equity plans, and agreements, is provided, with indications of whether they are filed with the current Form 10-K or incorporated by reference[308](index=308&type=chunk) [ITEM 16. Form 10-K Summary](index=58&type=section&id=Item%2016.%20Form%2010-K%20Summary) This item indicates that no Form 10-K Summary is provided - **No Form 10-K Summary** is included in this report[310](index=310&type=chunk) [Signatures](index=59&type=section&id=Signatures) This section contains the required signatures of the registrant's authorized officers and directors, affirming the filing of the Annual Report on Form 10-K - The report is **signed by the Chief Executive Officer (Principal Executive Officer), Principal Financial and Accounting Officer, and Directors**, confirming its submission[313](index=313&type=chunk)[314](index=314&type=chunk)[316](index=316&type=chunk)[317](index=317&type=chunk)

Core Insights - Amesite Inc. reported a 63% revenue growth for its NurseMagic™ platform following the launch of its census-based Enterprise subscription model on July 14, 2025, with Enterprise sales now surpassing B2C sales, indicating increased demand from post-acute care providers [1] - The company is addressing the upcoming regulatory changes from the Centers for Medicare & Medicaid Services (CMS) that will increase documentation burdens, with its AI-powered HOPE automation solution designed to streamline compliance and reimbursement processes [2][3] Company Overview - Amesite Inc. is focused on transforming the $330 billion home and healthcare segments with its AI-driven solutions, particularly the NurseMagic™ platform, which reduces healthcare documentation time from 20 minutes to just 20 seconds [5] - The platform is utilized by over 100 professions and is designed to enhance operational efficiency while ensuring compliance with HIPAA regulations [5] Market Dynamics - The post-acute care market is growing at a compound annual growth rate (CAGR) of 8%, outpacing the acute care market, which presents significant opportunities for companies like Amesite [3] - The total addressable market for Amesite's solutions is expanding as the company shifts its focus from individual employees to serving entire healthcare organizations, leveraging AI technology as a competitive advantage [2]

Core Insights - Amesite Inc. has launched the NurseMagic™ Enterprise Tier to address the needs of mid- and large-scale post-acute healthcare providers, integrating AI capabilities into existing workflows to enhance operational efficiency and compliance [1][3] - The new pricing model ties costs to patient census rather than headcount, allowing for scalable revenue growth as care delivery expands, which is expected to unlock more opportunities for enterprise adoption [3][4] - NurseMagic™ Enterprise includes features such as seamless EMR integration, automated interdisciplinary team reporting, and custom-formatted documentation, all designed to streamline operations and improve compliance [4][5] Product Features - NurseMagic™ Enterprise enables bi-directional data transfer with EMRs, allowing documentation to populate directly into clinical systems, enhancing documentation efficiency [4] - The platform automates IDT reporting, saving time on compliance processes for home health and hospice agencies without requiring changes to existing team structures [4] - Custom documentation templates are supported, ensuring compliance with payer and regulatory requirements while improving speed and consistency [4] Market Positioning - The launch of NurseMagic™ Enterprise will replace the entry-level B2B Teams plan, offering two tiers: Teams Plus+ for smaller patient censuses and the new Enterprise Tier for larger deployments [3][5] - Amesite aims to capture more value from each organization served, positioning itself for stronger recurring revenue growth through these enhanced offerings [5] - NurseMagic™ is currently utilized across all 50 U.S. states and 21 countries, with a focus on rapid product cycles and sustained growth in the post-acute enterprise market [6][7] Company Overview - Amesite Inc. is an AI-driven company targeting the $330 billion home and healthcare segments, with its flagship product, NurseMagic™, significantly reducing documentation time from 20 minutes to just 20 seconds [7] - The platform is designed to meet HIPAA regulations while improving accuracy and efficiency, serving both B2B and B2C users [7]

Core Insights - Amesite Inc. has enhanced its NurseMagic™ app to support charting in 16 languages, addressing the needs of nearly 1 million ESL nurses in the U.S. [1][2] - The company reported a 2.4x quarter-on-quarter revenue increase, driven by the rapid adoption of NurseMagic™ and improved operating efficiency [4][5] Company Developments - NurseMagic™ now supports languages including English, Chinese, Hindi, Spanish, French, Portuguese, Russian, Indonesian, German, Japanese, Korean, Turkish, Italian, Ukrainian, Dutch, and Swedish [3] - The company has launched a higher-priced enterprise tier to meet growing B2B demand for increased capacity [4] - NurseMagic™ reduces documentation time for nurses from 20 minutes to just 20 seconds, enhancing operational efficiency [5] Market Positioning - The multilingual capability of NurseMagic™ positions Amesite to capture value in both domestic and international markets, particularly among the 19.2% of U.S. nurses who speak English as a second language [2][6] - The platform serves B2B and B2C users across 50 states and 21 countries, with seamless integration into healthcare workflows [5]

Financial Results - Amesite Inc. reported financial results for Q3 ended March 31, 2025, with a significant business update[5] - The press release detailing the financial results is included as Exhibit 99.1[7] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[4]

Core Insights - Amesite Inc. reported a significant revenue increase of 2.4 times from Q2/2025 to Q3/2025, driven by targeted sales and marketing efforts as well as product enhancements [1][2] - The company maintains a balanced revenue distribution between B2B and B2C sales, with a notable user growth of 1340% in Q3/2025 following the launch of paid subscriptions [2] - Amesite's flagship product, NurseMagic, is designed to streamline documentation for healthcare professionals, significantly reducing time spent on tasks from 20 minutes to just 20 seconds [3] Company Performance - The company has successfully reduced operating expenses while scaling sales, focusing on operational efficiencies and margin management to drive profitability [2] - Customer feedback indicates a strong product-market fit, with the company confident in its ability to deliver affordable solutions while maintaining healthy margins [2][3] - Recent product rollouts include enhancements for the hospice segment and compliance with HIPAA regulations, alongside a new higher-priced tier for B2B users [2] Market Position - Amesite targets large segments within the healthcare industry, including 16,700 skilled nursing and home health care facilities in the U.S., employing 1.38 million workers, and 8,514 hospice organizations with 407,692 employees [2] - The company serves a total of 5.2 million registered nurses (RNs) and 630,000 licensed practical nurses (LPNs) in the U.S., with rising demand across senior living, skilled nursing, and hospice sectors [2] - NurseMagic is utilized by over 100 professions, enhancing operational efficiency and financial performance across healthcare workflows [3]

Financial Performance - The company incurred a net loss of $2,693,100 for the nine months ended March 31, 2025, and a cumulative net loss of $40.5 million since its incorporation on November 14, 2017[92]. - Revenue for the three months ended March 31, 2025, was approximately $31,000, down from $34,000 for the same period in 2024, and revenue for the nine months ended March 31, 2025, was approximately $55,000 compared to $139,000 in 2024[112]. - The net loss for the three months ended March 31, 2025, was approximately $663,000, a decrease of about 53% compared to a net loss of approximately $1.4 million for the same period in 2024[123]. - For the nine months ended March 31, 2025, the net loss was approximately $2.7 million, which is about 16% lower than the $3.2 million loss for the same period in 2024[123]. Cash and Financing - As of March 31, 2025, the company's cash and cash equivalents totaled $2,858,963, an increase from $2,071,016 as of June 30, 2024[101][107]. - The company has raised net proceeds of approximately $11,760,000 from private placement financing transactions from its incorporation to September 30, 2020[97]. - The company has plans to generate cash through financing transactions, including offerings of common stock, but these plans are subject to market conditions and uncertainty[94][105]. Expenses - General and administrative expenses for the three months ended March 31, 2025, were approximately $428,000, a decrease from $1,135,000 in the same period in 2024[117]. - Technology and content development expenses for the nine months ended March 31, 2025, were approximately $524,000, down from $889,000 for the same period in 2024[119]. - Sales and marketing expenses for the three months ended March 31, 2025, were approximately $118,000, compared to $139,000 for the same period in 2024[121]. - Interest income for the nine months ended March 31, 2025, was approximately $53,000, down from $148,000 for the same period in 2024[122]. - Capital asset additions for the nine months ended March 31, 2025, were $292,200, compared to $228,000 for the same period in 2024, indicating an increase of approximately 28%[124]. Compliance and Internal Controls - The Company received a Nasdaq deficiency letter on November 26, 2024, due to non-compliance with the Stockholders' Equity Requirement of $2,500,000[125]. - On January 10, 2025, the Company submitted a plan to regain compliance and believed it had regained compliance following a public offering[126]. - The Company reported material weaknesses in its internal controls over financial reporting, which could lead to potential misstatements in financial statements[130][131]. - Management identified deficiencies in controls related to journal entries and stock compensation expense calculations[132]. - The Company plans to document processes and controls to address the identified material weaknesses and improve internal control effectiveness[136]. - There were no changes in internal control over financial reporting that materially affected the Company during the period ended March 31, 2025[135]. - The Company intends to take all reasonable measures to maintain compliance with Nasdaq Listing Rules[127]. Business Development - The company is focusing on developing AI-powered B2B and B2C solutions, with the NurseMagic app being a key product that has gained traction[114].

Core Insights - Amesite Inc. has launched a higher-priced enterprise tier, Teams Plus+, for its NurseMagic app, responding to increased demand from businesses for greater capacity and advanced analytics [1][2] - The new tier allows businesses to access real-time insights and productivity metrics, which are essential for improving efficiency and reducing costs [2][3] Company Overview - Amesite Inc. is focused on transforming the $330 billion home and healthcare segments with its AI-driven solutions [3] - NurseMagic significantly reduces documentation time for healthcare professionals from 20 minutes to just 20 seconds, enhancing operational efficiency and financial performance [3] - The platform complies with HIPAA regulations and is utilized by over 100 professions across 50 states and 21 countries, offering integration into healthcare workflows and multilingual support [3] Market Response - The introduction of Teams Plus+ is a direct response to B2B customer requests for more capacity, with positive reviews indicating strong market demand [2] - The company anticipates increased sales and customer retention as businesses scale their usage of NurseMagic [2] - The demand for enhanced services highlights the successful product adoption within just eight months of the B2B solution's public launch [2]

Core Insights - Amesite Inc. announced that its product NurseMagic™ now meets HIPAA requirements for all users, ensuring compliance for both individual and enterprise usage in handling sensitive healthcare information [1][2] - The company has reported increased sales in B2B following its earlier compliance with HIPAA for enterprise customers [1][4] Company Developments - NurseMagic™ provides a Business Associate Agreement (BAA) for all users, allowing care providers to securely enter patient details and personally identifiable health information (PHI) [2] - The application is designed to integrate seamlessly with existing electronic medical record (EMR) systems, enhancing its utility across various healthcare software infrastructures [2][6] Market Position and Growth - NurseMagic™ has gained traction in both B2B and B2C sales, with a growing user base and recurring revenue [4] - The healthcare software-as-a-service market is projected to exceed $90 billion by 2033, with a compound annual growth rate (CAGR) of nearly 11% [5] Product Impact - NurseMagic™ has been adopted by professionals in over 130 different roles, demonstrating its effectiveness in improving care delivery and operational efficiency [3][6] - The product significantly reduces documentation time for healthcare workers from 20 minutes to just 20 seconds, enhancing overall productivity [6]